Given the distinct metabolic characteristics of cancer cells, targeting metabolic pathways has emerged as a promising strategy in cancer therapy. Inhibitors of glycolysis, mitochondrial function, and other metabolic processes are being investigated for their potential to selectively kill cancer cells while sparing normal cells. For instance, drugs like metformin and dichloroacetate are being studied for their effects on altering cancer cell metabolism.
